🔎 Trials Near Me

ホーム › ループス › カリフォルニア州

カリフォルニア州におけるループスの臨床試験

カリフォルニア州内の拠点で、ループスに関する27件の研究が参加者を募集しています。

カリフォルニア州内の都市

公式研究テキスト(英語)

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

  • Sl0044 50737, Beverly Hills
  • Sl0044 50775, Beverly Hills
  • Sl0044 50257, La Jolla
  • 他6件
被験者募集中第3相
16歳以上 · 全性別 · 2026/10/02更新 · NCT06617325

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

  • Ronald Reagan UCLA Medical Center, Los Angeles
被験者募集中第2相
18歳〜100歳 · 全性別 · 2026/10/01更新 · NCT05268289

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

  • Wallace & Lee Center, Beverly Hills
  • Arthritis & Osteoporosis Medical Center, Inc - La Palma, La Palma
  • University of California San Diego, San Diego
  • 他3件
被験者募集中第2相
18歳〜74歳 · 全性別 · 2026/10/01更新 · NCT07409181

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

  • Providence Medical Center, Burbank
  • Advanced Medical Research, La Palma
被験者募集中第3相
12歳〜100歳 · 全性別 · 2026/10/01更新 · NCT06133972

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

  • Research Site, Los Angeles
被験者募集中第3相
5歳〜17歳 · 全性別 · 2026/09/30更新 · NCT05835310

A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

  • Research Site, Fontana
  • Research Site, La Jolla
  • Research Site, La Palma
  • 他3件
被験者募集中第3相
18歳〜70歳 · 全性別 · 2026/09/25更新 · NCT07430306

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

  • David S Hallegua MD A Professional Corporation, Beverly Hills
  • Providence Medical Foundation, Fullerton
  • Southland Arthritis and Osteoporosis Medical Center Inc dba Southland Arthritis, Hemet
  • 他5件
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/25更新 · NCT07438496

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  • University of California Davis Comprehensive Cancer Center, Sacramento
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/23更新 · NCT03816345

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

  • Research Site, Fullerton
被験者募集中第1相
18歳〜65歳 · 全性別 · 2026/09/18更新 · NCT07201558

Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis

  • University of California San Francisco - Zuckerberg San Francisco General, San Francisco
被験者募集中第1相
18歳〜60歳 · 全性別 · 2026/09/14更新 · NCT06975787

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

  • Inland Rheumatology Clinical Trials, Inc., Upland
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/14更新 · NCT07355218

A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis

  • Wallace Rheumatic Studies Center, Beverly Hills
  • Kaiser Permanente Fontana, Fontana
  • Providence Medical Foundation, Fullerton
  • 他2件
被験者募集中第2相
12歳〜70歳 · 全性別 · 2026/09/14更新 · NCT07570862

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

  • Dermatology Research Associates - 300204025, Los Angeles
  • Cohen Medical Centers, Thousand Oaks
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/11更新 · NCT07332481

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

  • Research Site, San Francisco
  • Research Site, Stanford
被験者募集中第1/2相
18歳〜70歳 · 全性別 · 2026/09/10更新 · NCT06897930

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

  • Loma Linda University Medical Center, Loma Linda
被験者募集中第1相
18歳〜74歳 · 全性別 · 2026/09/10更新 · NCT07085104

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

  • Local Institution - 0054, La Jolla
  • Local Institution - 0001, La Palma
  • Local Institution - 0071, Los Angeles
  • 他1件
被験者募集中観察研究
16歳以上 · 全性別 · 2026/09/03更新 · NCT07175285

FT839 in Autoimmune Diseases

  • Providence Medical Foundation, Fullerton
被験者募集中第1/2相
18歳〜70歳 · 全性別 · 2026/09/02更新 · NCT07800871

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

  • UC San Diego Health, La Jolla
  • Stanford University Medical Center, Redwood City
被験者募集中第1相
18歳〜70歳 · 全性別 · 2026/08/28更新 · NCT06925542

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

  • University of California Irvine, Orange
  • UC Davis Health, Sacramento
被験者募集中第1/2相
18歳〜65歳 · 全性別 · 2026/08/26更新 · NCT06121297

Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

  • University of California, Los Angeles, Los Angeles
  • University of California: San Diego, San Diego
被験者募集中第3相
55歳以上 · 全性別 · 2026/08/20更新 · NCT05799378

Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA

  • Carewell Arthritis Center, Apple Valley
  • Attune Health Research Inc, Beverly Hills
  • Covina Arthritis Clinic, Covina
  • 他4件
被験者募集中第1相
18歳〜75歳 · 全性別 · 2026/07/20更新 · NCT07237659

A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants

  • US06-0, La Palma
被験者募集中第1/2相健康なボランティア歓迎
18歳〜70歳 · 全性別 · 2026/06/02更新 · NCT06625671

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

  • Wallace Rheumatic Center, Beverly Hills
  • Providence Medical Foundation, Fullerton
  • University of California Irvine, Irvine
  • 他2件
被験者募集中第1相
12歳〜70歳 · 全性別 · 2026/05/22更新 · NCT06308978

Lupus Landmark Study: A Prospective Registry and Biorepository

  • Wallace Rheumatic Studies Center, Beverly Hills
  • UCLA, Los Angeles
被験者募集中観察研究
18歳〜110歳 · 全性別 · 2026/04/15更新 · NCT05934149

ClinicalTrials.govより、2026/10/03時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。